Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.27 USD | +5.43% | -2.95% | -22.36% |
Apr. 30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
Mar. 27 | North American Morning Briefing : Stocks Edge -2- | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.36% | 36.1M | |
-0.24% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.54% | 24.63B | |
-23.65% | 18.2B | |
+26.90% | 12.01B | |
-3.17% | 11.76B | |
+12.61% | 10.4B | |
-4.11% | 9.94B |
- Stock Market
- Equities
- MRKR Stock
- News Marker Therapeutics, Inc.
- Correction: Marker Therapeutics Says MT-401 Non-clinical Data Show Anti-Tumor Activity Against Acute Myeloid Leukemia